Login to Your Account

Genta Plunges on Failed Phase III Survival Analysis for Genasense

By Trista Morrison

Tuesday, May 24, 2011
After more than a decade of development, Genta Inc. appears to be putting beleaguered antisense drug Genasense (oblimersen sodium) out of its misery.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription